RESUMO
PURPOSE: To assess the impact of an intervention for baker's allergy and asthma in supermarket bakeries. METHODS: A group randomised trial conducted in 31 bakeries (n = 337 bakers) that were randomly assigned to one of two intervention groups (n = 244 bakers) and a control group (n = 93 bakers). Health data collected prior to and 1-year after the intervention included information obtained from an ECRHS questionnaire; tests for atopy and serum-specific IgE to cereal flours; fractional exhaled nitric oxide (FeNO). Data from the two intervention groups were combined to form one intervention group for purposes of the statistical analysis. RESULTS: At 1 year of follow-up, the incidence and level of decline of work-related ocular-nasal and chest symptoms, sensitisation status and elevated FeNO (FeNO > 25 ppb) was similar in both intervention and control groups. The mean FeNO difference was also similar across both groups (2.2 ppb vs 1.7 ppb, p = 0.86). In those with FeNO > 25 ppb at baseline, the decline was greater in the intervention compared to control group (16.9 ppb vs 7.7 ppb, p = 0.24). Multivariate logistic regression models (adjusting for smoking, baseline sensitisation to cereal flour, baseline FeNO > 25 ppb) did not demonstrate an appreciable FeNO decline (≥ 10%) in the intervention compared to control group. However, stratification by the presence of work-related ocular-nasal symptoms in bakers at baseline demonstrated a significant FeNO decline (≥ 10%) in the intervention compared to the control group (OR 3.73, CI 1.22-11.42). CONCLUSION: This study demonstrates some evidence of an intervention effect on FeNO 1 year after an intervention, particularly in bakers with work-related ocular-nasal symptoms.
Assuntos
Poluentes Ocupacionais do Ar/imunologia , Asma Ocupacional/prevenção & controle , Exposição Ocupacional/prevenção & controle , Rinite Alérgica Perene/prevenção & controle , Adulto , Poluentes Ocupacionais do Ar/efeitos adversos , Asma Ocupacional/imunologia , Grão Comestível/imunologia , Feminino , Farinha/efeitos adversos , Manipulação de Alimentos/instrumentação , Manipulação de Alimentos/métodos , Humanos , Imunoglobulina E/sangue , Masculino , Pessoa de Meia-Idade , Óxido Nítrico/metabolismo , Material Particulado/efeitos adversos , Distribuição Aleatória , Rinite Alérgica Perene/imunologia , África do Sul , Supermercados , alfa-Amilases/análiseRESUMO
PROPOSE: Allergic rhinitis (AR) is a very common, chronic and global health problem. In the last two decades, the efficiency of barrier-enforcing measures in AR has been investigated. In this study, we aimed to evaluate the effect of allergen-blocker mechanical barrier gel (MBG) (AlerjiSTOP®) treatment on symptoms and quality of life score (QoLS) in patients with seasonal and perennial allergic rhinitis. METHODS: A single-center, prospective study was conducted between January 2017 and May 2018. Patients diagnosed with allergic rhinitis with a visual analogue scale (VAS) of 5 or higher (moderate/severe) were enrolled in the study. Patients were evaluated in terms of VAS, nasal symptom score (NSS), ocular symptom score (OSS), total symptom score (TSS) and QoLS at baseline, 1 week and 1 month of MBG treatment. RESULTS: A total of 83 patients with AR were enrolled in the study. Clinical and laboratory examinations showed that 50 (60.2%) patients were mono-sensitized. Allergen-blocker mechanical barrier gel treatment was performed as monotherapy in 22 (26.5%) patients. Median VAS, NSS, OSS and TSS decreased from 7 to 4, 8 to 3, 4 to 0 and 12 to 4, respectively (p < 0.0001). Correlation analysis revealed positive correlations between lower pediatric rhinoconjunctivitis quality of life questionnaire scores for patients under 12 years of age and decrease in VAS, NSS and TSS (r = 0.380, p = 0.008; r = 0.544, p < 0.0001; r = 0.543, p < 0.0001). Positive correlations were detected between lower rhinoconjunctivitis quality of life questionnaire (self-administered) scores for patients ≥ 12 years of age and decrease in VAS, NSS, OSS and TSS (r = 0.703, p < 0.0001; r = 0.465, p = 0.005; r = 0.526, p = 0.001; r = 0.624, p < 0.0001). CONCLUSION: In conclusion, we found significant decrease in all symptom scores and improvement in QoLS of patients treated with MBG as monotherapy and combination therapy.
Assuntos
Alérgenos , Conjuntivite Alérgica/prevenção & controle , Géis/administração & dosagem , Qualidade de Vida , Rinite Alérgica Perene/prevenção & controle , Rinite Alérgica Sazonal/prevenção & controle , Administração Intranasal , Adolescente , Criança , Conjuntivite Alérgica/diagnóstico , Feminino , Humanos , Masculino , Nariz , Estudos Prospectivos , Rinite Alérgica Perene/diagnóstico , Rinite Alérgica Sazonal/diagnóstico , Inquéritos e Questionários , Escala Visual AnalógicaRESUMO
BACKGROUND: Nasal hyperreactivity (NHR) is an important clinical feature of allergic rhinitis (AR). The efficacy of MP29-02 (azelastine hydrochloride (AZE) and fluticasone propionate [FP]) nasal spray on local inflammatory mediators and NHR in AR is unknown. We tested if MP29-02 decreases inflammatory mediators and NHR in AR and if this effect is due to restoration of nasal epithelial barrier function. METHODS: A 4-week double-blinded placebo-controlled trial with MP29-02 treatment was conducted in 28 patients with house dust mite (HDM) AR. The presence of NHR was evaluated by measuring reduction in nasal flow upon cold dry air exposure. The effects of AZE ± FP on barrier integrity and airway inflammation were studied in a murine model of HDM-induced NHR and on reduced activation of murine sensory neurons and human mast cells. RESULTS: MP29-02 but not placebo reduced NHR (P < .0001 vs P = .21), levels of substance P (P = .026 vs P = .941), and ß-hexosaminidase (P = .036 vs P = .632) in human nasal secretions. In wild-type C57BL6 mice, the reduction in ß-hexosaminidase levels (P < .0001) by AZE + FP treatment upon HDM challenge was found in parallel with a decreased transmucosal passage (P = .0012) and completely reversed eosinophilic inflammation (P = .0013). In vitro, repeated applications of AZE + FP desensitized sensory neurons expressing the transient receptor potential channels TRPA1 and TRPV1. AZE + FP reduced MC degranulation to the same extent as AZE alone. CONCLUSION: MP29-02 treatment reduces inflammatory mediators and NHR in AR. The effects of AZE + FP on MC degranulation, nasal epithelial barrier integrity, and TRP channels provide novel insights into the pathophysiology of allergic rhinitis.
Assuntos
Androstadienos/uso terapêutico , Antialérgicos/uso terapêutico , Mucosa Nasal/efeitos dos fármacos , Ftalazinas/uso terapêutico , Rinite Alérgica Perene/prevenção & controle , Adulto , Animais , Método Duplo-Cego , Combinação de Medicamentos , Feminino , Humanos , Masculino , Mastócitos/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos C57BL , Mucosa Nasal/imunologia , Pyroglyphidae/imunologia , Rinite Alérgica Perene/imunologia , Adulto JovemRESUMO
OBJECTIVE: Introduction: According to the European Academy of Allergology and Clinical Immunology (EAACI, 2016), allergy is the most common chronic disease in Europe. The aim: The aim of the investigation is to study the spread of risk factors of allergic reactions in children who are 8-9 years old of Poltava region. PATIENTS AND METHODS: Materials and methods: The investigation included two stages: the 1st contained interviewing; the 2nd one - additional clinical and lab investigation of children, who require the further diagnosis specification. RESULTS: Results: 1068 children who are 8-9 years old were interviewed based on questionnaires: 56,2% males and 43,8% females. Children were divided into residents (49,2%), and villagers (50,8%). In order to identify allergic diseases the division in family was the next: the presence of bronchial asthma was present in 38 people (3,6%), allergic rhinitis or allergic conjunctivitis - 128 people (12,0%), atopic dermatitis - 54 people (5,1%), food allergy - 129 people (12,1%), medicinal allergy - 25 people (11,7%). Analyzing the influence of trigger factors, it should be noted that in the risk group there are children who received cow's milk as substitutes for breast milk (38.1%), children who had a history of helminthal invasion (19.6%), children where parents smoke (45.9%), one third of parents (31.9%) complained of frequent respiratory viral infections in their children. CONCLUSION: Conclusions: Presented epidemiological investigation allowed studying the prevalence of diagnosed allergic diseases in children of Poltava region and determining children's category who require additional diagnostics of chronic allergic diseases.
Assuntos
Asma/epidemiologia , Dermatite Atópica/epidemiologia , Hipersensibilidade Alimentar/epidemiologia , Rinite Alérgica Perene/epidemiologia , Asma/prevenção & controle , Criança , Conjuntivite Alérgica/epidemiologia , Dermatite Atópica/prevenção & controle , Feminino , Hipersensibilidade Alimentar/prevenção & controle , Nível de Saúde , Humanos , Exposição por Inalação/prevenção & controle , Masculino , Prevalência , Prevenção Primária/métodos , Rinite Alérgica Perene/prevenção & controle , Poluição por Fumaça de Tabaco/efeitos adversos , UcrâniaRESUMO
BACKGROUND: Almost a quarter of the world population suffers from IgE-mediated allergies. T cells and IgG-producing B cells can produce protection, but treatment for disease is laborious with unsatisfactory patient compliance. OBJECTIVE: We sought to identify whether paediatric allergy vaccines affected later allergen sensitization and onset of disease when used prophylactically. METHODS: A murine model of anaphylaxis was applied. Mice were first immunized with monovalent or multivalent allergy vaccines that also contained aluminium hydroxide and CpG oligodeoxynucleotide as adjuvants. Later, the mice were sensitized by multiple low-dose injections of aluminium-adsorbed allergen. After a dormant period, the mice were challenged systemically with high-dose allergen, and the clinical signs of anaphylaxis were recorded. Throughout the immunization and sensitization periods, blood was collected for serological testing. RESULTS: Immunization with allergy vaccines produced antigen-specific protection against sensitization as measured by systemic anaphylaxis in mice. The long-term effect was observed both after juvenile (5-6 weeks) and neonatal (7 days) vaccination. Monovalent and pentavalent vaccines were protective to a similar level. Protection was associated with increased secretion of IgG2a and production of IFN-γ. Protection could also be transferred to sensitized mice via serum or via CD25-positive CD4 T cells. CONCLUSION AND CLINICAL RELEVANCE: Prophylactic and multivalent allergy vaccines in juvenile and neonatal mice protected against later sensitization and anaphylaxis. Such treatment may provide a rational measure for future management of allergen-related diseases and their strong socio-economic impact on daily life.
Assuntos
Anafilaxia/imunologia , Anafilaxia/prevenção & controle , Proteção Cruzada/imunologia , Vacinas/imunologia , Transferência Adotiva , Alérgenos/imunologia , Animais , Modelos Animais de Doenças , Feminino , Humanos , Esquemas de Imunização , Imunoglobulina E/sangue , Imunoglobulina E/imunologia , Imunoglobulina G/sangue , Imunoglobulina G/imunologia , Camundongos , Ovalbumina/efeitos adversos , Rinite Alérgica , Rinite Alérgica Perene/prevenção & controleRESUMO
BACKGROUND: Healthy gut microflora is essential for oral tolerance and immunity. A promising approach to preventing allergic diseases in genetically at-risk infants is to introduce administration of probiotics early in life when their immune system is still relatively immature. OBJECTIVE: In this follow-up study, we aim to determine if early-life supplementation with strains of probiotics has any long-term effect on allergic outcomes. METHODS: We analyzed the charts and electronic databases of the PROMPT (Probiotics in Milk for the Prevention of Atopy Trial) study cohort. This cohort consisted of 253 infants at risk for allergy who were administered cow's milk supplemented with or without probiotics from the first day of life to the age of 6 months. The cohort was then followed up until the children were 5 years old and clinical outcomes were assessed. RESULTS: Of the 253 children recruited into the study, 220 (87%) completed the follow-up. At the age of 5 years, there were no significant differences between the groups in the proportion of children who had developed any asthma, allergic rhinitis, eczema, food allergy and sensitization to inhalant allergens. Similar growth rates were observed in both groups. CONCLUSIONS: The supplementation of probiotics in early childhood did not play a role in the prevention of allergic diseases. Clinical/Key Message: Early-life supplementation with probiotics did not change allergic outcomes at 5 years of age.
Assuntos
Eczema/imunologia , Hipersensibilidade Alimentar/imunologia , Hipersensibilidade/imunologia , Probióticos/uso terapêutico , Rinite Alérgica Perene/imunologia , Fatores Etários , Animais , Povo Asiático , Criança , Pré-Escolar , Eczema/prevenção & controle , Feminino , Hipersensibilidade Alimentar/prevenção & controle , Humanos , Hipersensibilidade/prevenção & controle , Lactente , Estudos Longitudinais , Masculino , Rinite Alérgica Perene/prevenção & controle , Falha de TratamentoRESUMO
Fat-soluble vitamins A, E and K have been shown to play roles in immunity and inflammation, but studies on child allergic disease have been few and inconsistent. The aim of the present study was to examine the relationship between maternal intake of vitamins A, E and K in mid-pregnancy and child asthma and allergic rhinitis. We used data on 44 594 mother-child pairs from the Danish National Birth Cohort. Maternal intake of fat-soluble vitamins was calculated based on the information from a validated FFQ completed in mid-pregnancy. At 18 months, interviews with the mothers were conducted to evaluate doctor-diagnosed child asthma. At age 7 years, we assessed child asthma and allergic rhinitis using questions from the International Study of Asthma and Allergies in Childhood questionnaire and by national registries on hospital contacts and medication use. Current asthma was defined as asthma diagnosis and wheeze in the past 12 months by maternal report. We calculated multivariable risk ratios and 95 % CI by comparing the highest v. lowest quintile (Q) of maternal vitamin A, E and K intake in relation to child allergic disease outcomes. Maternal total vitamin K intake was directly associated with ever admitted asthma (Q5 v. Q1: 1·23, 95 % CI 1·01, 1·50) and current asthma at 7 years (Q5 v. Q1: 1·30, 95 % CI 0·99, 1·70). Weak inverse associations were present for maternal vitamin A and E intake during pregnancy with child allergic rhinitis. Maternal vitamin K intake during pregnancy may increase the risk of child asthma, and should be explored further on a mechanistic level. Conversely, maternal vitamin A and E intake may protect against child allergic rhinitis.
Assuntos
Asma/epidemiologia , Efeitos Tardios da Exposição Pré-Natal , Rinite Alérgica Perene/epidemiologia , Vitamina A/administração & dosagem , Vitamina E/administração & dosagem , Vitamina K/administração & dosagem , Adulto , Asma/etiologia , Asma/prevenção & controle , Criança , Dinamarca , Dieta , Suplementos Nutricionais , Feminino , Humanos , Lactente , Estudos Longitudinais , Masculino , Gravidez , Cuidado Pré-Natal/métodos , Sistema de Registros , Rinite Alérgica , Rinite Alérgica Perene/etiologia , Rinite Alérgica Perene/prevenção & controle , Inquéritos e QuestionáriosRESUMO
State-of-the-art documents like ARIA and EPOS provide clinicians with evidence-based treatment algorithms for allergic rhinitis (AR) and chronic rhinosinusitis (CRS), respectively. The currently available medications can alleviate symptoms associated with AR and RS. In real life, a significant percentage of patients with AR and CRS continue to experience bothersome symptoms despite adequate treatment. This group with so-called severe chronic upper airway disease (SCUAD) represents a therapeutic challenge. The concept of control of disease has only recently been introduced in the field of AR and CRS. In case of poor control of symptoms despite guideline-directed pharmacotherapy, one needs to consider the presence of SCUAD but also treatment-related, diagnosis-related and/or patient-related factors. Treatment-related issues of uncontrolled upper airway disease are linked with the correct choice of treatment and route of administration, symptom-oriented treatment and the evaluation of the need for immunotherapy in allergic patients. The diagnosis of AR and CRS should be reconsidered in case of uncontrolled disease, excluding concomitant anatomic nasal deformities, global airway dysfunction and systemic diseases. Patient-related issues responsible for the lack of control in chronic upper airway inflammation are often but not always linked with adherence to the prescribed medication and education. This review is an initiative taken by the ENT section of the EAACI in conjunction with ARIA and EPOS experts who felt the need to provide a comprehensive overview of the current state of the art of control in upper airway inflammation and stressing the unmet needs in this domain.
Assuntos
Rinite Alérgica Perene/prevenção & controle , Sinusite/prevenção & controle , Doença Crônica , Humanos , Rinite Alérgica , Rinite Alérgica Perene/diagnóstico , Rinite Alérgica Perene/terapia , Fatores de Risco , Sinusite/diagnóstico , Sinusite/terapiaRESUMO
OBJECTIVE AND DESIGN: This study is aimed at exploring the role of neurokinin-1 receptor (NK-1R) in the development of allergic rhinitis (AR) in rats. METHODS: Sprague-Dawley rats were sensitized and challenged with ovalbumin to induce AR. The rats were treated intranasally with saline, control, or NK-1R-specific small interfering RNA (siRNA) before and during the challenge period. The numbers of sneezes and nose rubs and amount of nasal secretion in individual rats were measured. The levels of NK-1R expression in the nasal mucosal tissues after the last challenge were determined. The numbers of eosinophils in the collected nasal lavage fluid and the levels of serum interleukin (IL)-5 in individual rats were determined. RESULTS: The levels of NK-1R expression in the nasal mucosal tissues of the AR rats that had been treated with saline or control siRNA were significantly higher than those in the healthy controls and the rats treated with NK-1R-specific siRNA, demonstrating NK-1R silencing. Furthermore, knockdown of NK-1R expression significantly reduced the amounts of sneezing, nose rubbing, and nasal secretions in AR rats. Knockdown of NK-1R expression also significantly eliminated eosinophil infiltration in the nasal tissues and reduced the levels of serum IL-5 in rats. CONCLUSIONS: Knockdown of NK-1R expression decreased allergic inflammation in nasal mucosal tissues and alleviated the allergic rhinitis symptoms, suggesting that NK-1R may be a critical mediator of the development of AR.
Assuntos
Receptores da Neurocinina-1/genética , Rinite Alérgica Perene/prevenção & controle , Alérgenos , Animais , Eosinófilos/citologia , Eosinófilos/efeitos dos fármacos , Técnicas de Silenciamento de Genes , Interleucina-5/imunologia , Contagem de Leucócitos , Masculino , Líquido da Lavagem Nasal/citologia , Ovalbumina , RNA Interferente Pequeno/genética , Ratos , Ratos Sprague-Dawley , Rinite Alérgica , Rinite Alérgica Perene/imunologiaRESUMO
Maternal fish intake during pregnancy may influence the risk of child asthma and allergic rhinitis, yet evidence is conflicting on its association with these outcomes. We examined the associations of maternal fish intake during pregnancy with child asthma and allergic rhinitis. Mothers in the Danish National Birth Cohort (n 28 936) reported their fish intake at 12 and 30 weeks of gestation. Using multivariate logistic regression, we examined the associations of fish intake with child wheeze, asthma and rhinitis assessed at several time points: ever wheeze, recurrent wheeze (>3 episodes), ever asthma and allergic rhinitis, and current asthma, assessed at 18 months (n approximately 22,000) and 7 years (n approximately 17,000) using self-report and registry data on hospitalisations and prescribed medications. Compared with consistently high fish intake during pregnancy (fish as a sandwich or hot meal > or equal to 2-3 times/week), never eating fish was associated with a higher risk of child asthma diagnosis at 18 months (OR 1·30, 95% CI 1·05, 1·63, P=0·02), and ever asthma by hospitalisation (OR 1·46, 95% CI 0·99, 2·13, P=0·05) and medication prescription (OR 1·37, 95% CI 1·10, 1·71, P=0·01). A dose-response was present for asthma at 18 months only (P for trend=0·001). We found no associations with wheeze or recurrent wheeze at 18 months or with allergic rhinitis. The results suggest that high (v. no) maternal fish intake during pregnancy is protective against both early and ever asthma in 7-year-old children.
Assuntos
Asma/prevenção & controle , Dieta , Peixes , Rinite Alérgica Perene/prevenção & controle , Alimentos Marinhos , Adolescente , Adulto , Animais , Criança , Dinamarca , Feminino , Hospitalização , Humanos , Modelos Logísticos , Estudos Longitudinais , Masculino , Refeições , Mães , Razão de Chances , Gravidez , Sons Respiratórios , Rinite Alérgica , Risco , Autorrelato , Adulto JovemRESUMO
The increasing prevalence of allergic disease has been linked to reduced microbial exposure in early life. Probiotics have recently been advocated for the prevention and treatment of allergic disease. This article summarises recent publications on probiotics in allergic disease, focusing on clinical studies of prevention or treatment of allergic disease. Studies employing the combined administration of pre-natal and post-natal probiotics suggest a role for certain probiotics (alone or with prebiotics) in the prevention of eczema in early childhood, with the pre-natal component of treatment appearing to be important for beneficial effects. On the other hand, current data are insufficient to support the use of probiotics for the treatment of established allergic disease, although recent studies have highlighted new hope in this area. Probiotic bacteria continue to represent the most promising intervention for primary prevention of allergic disease, and well-designed definitive intervention studies should now be a research priority.
Assuntos
Hipersensibilidade Imediata/terapia , Probióticos/uso terapêutico , Asma/prevenção & controle , Asma/terapia , Dermatite Atópica/prevenção & controle , Dermatite Atópica/terapia , Hipersensibilidade Alimentar/prevenção & controle , Hipersensibilidade Alimentar/terapia , Humanos , Hipersensibilidade Imediata/prevenção & controle , Prebióticos , Rinite Alérgica Perene/prevenção & controle , Rinite Alérgica Perene/terapia , SimbióticosRESUMO
Allergen-specific immunotherapy (ASIT) the only disease-modifying treatment for IgE-mediated allergies is characterized with long treatment duration and high risk of side effects. We investigated the safety, immunogenicity and efficacy of a novel ASIT, called DermAll, in an experimental allergic rhinitis model. We designed and characterized DermAll-OVA, a synthetic plasmid pDNA/PEIm nanomedicine expressing ovalbumin (OVA) as model allergen. DermAll-OVA was administered topically with DermaPrep device to target Langerhans cells. To detect the clinical efficacy of DermAll ASIT we quantified the nasal symptoms and characterized the immunomodulatory activity of DermAll ASIT by measuring cytokine secretion after OVA-stimulation of splenocytes and antibodies from the sera. In allergic mice DermAll ASIT was as safe as Placebo, balanced the allergen-induced pathogenic TH2-polarized immune responses, and decreased the clinical symptoms by 52% [32%, 70%] compared to Placebo. These studies suggest that DermAll ASIT is safe and should significantly improve the immunopathology and symptoms of allergic diseases. FROM THE CLINICAL EDITOR: A novel allergen-specific immunotherapy for IgE-mediated allergies is presented in this paper, using an experimental allergic rhinitis model and a synthetic plasmid pDNA/PEIm nanomedicine expressing ovalbumin as model allergen. Over 50% reduction of symptoms was found as the immune system's balance was favorably altered toward more TH2-polarized immune responses.
Assuntos
Alérgenos/imunologia , Ovalbumina/imunologia , Rinite Alérgica Perene/imunologia , Rinite Alérgica Perene/prevenção & controle , Vacinas de DNA/imunologia , Vacinas de DNA/uso terapêutico , Administração Tópica , Alérgenos/genética , Animais , Citocinas/imunologia , Feminino , Imunização , Imunoglobulina E/sangue , Imunoglobulina E/imunologia , Células de Langerhans/imunologia , Células de Langerhans/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Nanomedicina , Ovalbumina/genética , Plasmídeos/administração & dosagem , Plasmídeos/genética , Plasmídeos/imunologia , Plasmídeos/uso terapêutico , Rinite Alérgica , Rinite Alérgica Perene/sangue , Células Th2/imunologia , Vacinas de DNA/administração & dosagem , Vacinas de DNA/genéticaRESUMO
Asthma frequently occurs in association with allergic rhinitis and a combined management approach has been suggested. The Control of Allergic Rhinitis and Asthma Test (CARAT) is the first questionnaire to assess control of both diseases concurrently. However, to have an impact on healthcare it needs to be disseminated and adopted. In this paper we discuss the dissemination of CARAT in different countries and its possible applications in primary care. At present, the adaptation of CARAT for use in different languages and cultures is being led by volunteer researchers and clinicians in 15 countries. Website and smartphone applications have been developed, and a free open model of distribution was adopted to contribute to the dissemination of CARAT. Examples of dissemination activities include distribution of leaflets and posters, educational sessions on the use of the questionnaire in the follow-up of patients, development of clinical studies, collaborations with professional organisations and health authorities, and the inclusion of CARAT in clinical guidelines. The adoption of innovations is an important challenge in healthcare today, and research on the degree of success of dissemination strategies using suitable methods and metrics is much needed. We propose that CARAT can be used in a range of settings and circumstances in primary care for clinical, research and audit purposes, within the overall aim of increasing awareness of the level of disease control and strengthening the partnership between patients and doctors in the management of asthma and rhinitis.
Assuntos
Asma/complicações , Asma/prevenção & controle , Disseminação de Informação , Atenção Primária à Saúde , Rinite Alérgica Perene/complicações , Rinite Alérgica Perene/prevenção & controle , Humanos , Rinite Alérgica , Inquéritos e QuestionáriosRESUMO
Specific immunotherapy (SIT) is a disease modifying treatment for allergic rhinitis (AR), with its benefits most evident in those who are refractory to medical treatment. It is used less frequently in UK than Europe/US. No data exist on SIT use in Ireland. We audited paediatric practice to evaluate patient selection, SIT modalities and adverse events (A.E.). A 9 item questionnaire was sent to Irish paediatricians, identified via the Irish Paediatric Surveillance Unit (IPSU) mailing list. 58 children have undertaken SIT (Subcutaneous SCIT =3, Sublingual = 55). This represents 0.01% of Irish children estimated to have AR. 33 (56%) had asthma; 18 (55%) had perennial asthma, 7 (21%) seasonal asthma. Adverse events occurred in 5 cases (8.6%). Three treatments (3-5%) were discontinued as a result. SIT is available across Ireland, though only extremely small numbers of children with AR are being treated yet. Co-morbid asthma is frequent and does not increase adverse events. This audit will raise awareness of SIT use for AR in Ireland.
Assuntos
Imunoterapia/métodos , Rinite Alérgica Perene/imunologia , Rinite Alérgica Perene/prevenção & controle , Adolescente , Criança , Feminino , Humanos , Irlanda , Masculino , Vigilância da População , Rinite Alérgica , Inquéritos e QuestionáriosRESUMO
There is comparatively little information on health-related quality of life (HRQoL) in subjects with allergic rhinitis (AR) or allergic rhinoconjunctivitis (AR/C) in countries beyond western Europe and North America. The primary aim of this investigation was therefore to review and assess the information in the public domain on HRQoL in AR/C patients from diverse regions of the world, represented by different countries, including Argentina, Australia, Brazil, Russia, Singapore, South Africa and Turkey. Second, in view of the absence of a standardized definition for 'AR control', the review aimed to determine whether a working definition of AR/C can be inferred from validated tests or other instruments documented to date. Despite the comparatively low number of studies, this review demonstrated that overall the symptoms of AR/C impair the HRQoL of patients in these regions by adversely impacting sleep, daily activities, physical and mental status and social functioning, similar to that demonstrated in much larger numbers of studies of AR/C patients in Europe and the United States. Furthermore, the findings of the review suggest that 'overall' control of the disease should encompass reduction of nasal and ocular symptoms, as well as improvements in HRQoL, comorbid conditions and cognition. Although some instruments are currently available for measuring control of AR, none are capable of assessing all these aspects, emphasizing the need to develop appropriate new instruments.
Assuntos
Conjuntivite Alérgica/fisiopatologia , Qualidade de Vida , Rinite Alérgica Perene/fisiopatologia , Argentina , Austrália , Brasil , Conjuntivite Alérgica/epidemiologia , Conjuntivite Alérgica/prevenção & controle , Humanos , Rinite Alérgica , Rinite Alérgica Perene/epidemiologia , Rinite Alérgica Perene/prevenção & controle , Federação Russa , Singapura , África do Sul , TurquiaRESUMO
BACKGROUND: Antioxidant intake may reduce the risk of allergic disease by protecting against oxidative tissue damage. Major sources of antioxidants in the Western world are fruits, vegetables (vitamin C, ß-carotene, α-tocopherol), meat and milk (selenium, magnesium, zinc). Children may exclude or eat less of some fruits and vegetables due to cross-reactivity between pollen and these foods, complicating assessment of causal relationships. OBJECTIVE: To investigate the association between dietary antioxidant intake and allergic disease, taking potential reverse causation into account. METHODS: Data on 2442 8-year-old children from the Swedish birth cohort study BAMSE were analysed. Children with completed parental questionnaires on exposures and health, including a food-frequency questionnaire and who provided a blood sample were included. Associations between antioxidant intake during the past year and current allergic disease were analysed using logistic regression. RESULTS: An inverse association was observed between intake of ß-carotene and rhinitis (OR(adj), highest vs. lowest quartile, 0.67, 95% CI 0.49-0.93). Magnesium intake was inversely related to asthma (OR(adj), 0.65, 95% CI 0.42-1.00) and atopic sensitisation (OR(adj), 0.78, 95% CI 0.61-1.00). Following exclusion of children who avoided certain fruits, vegetables or milk due to allergic symptoms (n = 285), the inverse association remained between magnesium intake and asthma (OR(adj), 0.58, 95% CI 0.35-0.98), whereas all other associations became non-significant. CONCLUSION AND CLINICAL RELEVANCE: Diet modifications due to allergy may affect the antioxidant intake and needs to be considered when investigating the relationship between diet and allergic disease. Magnesium intake seems to have a protective effect on childhood asthma.
Assuntos
Antioxidantes/administração & dosagem , Dieta , Antioxidantes/farmacologia , Ácido Ascórbico/administração & dosagem , Ácido Ascórbico/farmacologia , Asma/epidemiologia , Asma/etiologia , Asma/prevenção & controle , Criança , Estudos de Coortes , Feminino , Humanos , Hipersensibilidade Imediata/epidemiologia , Hipersensibilidade Imediata/etiologia , Hipersensibilidade Imediata/prevenção & controle , Magnésio/administração & dosagem , Magnésio/farmacologia , Masculino , Rinite Alérgica Perene/epidemiologia , Rinite Alérgica Perene/etiologia , Rinite Alérgica Perene/prevenção & controle , Inquéritos e Questionários , Suécia/epidemiologia , alfa-Tocoferol/administração & dosagem , alfa-Tocoferol/farmacologia , beta Caroteno/administração & dosagem , beta Caroteno/farmacologiaRESUMO
BACKGROUND: Interactions between Th1 and Th2 immune responses are of importance to the onset and development of allergic disorders. A Toll-like receptor 7 agonist such as AZD8848 may have potential as a treatment for allergic airway disease by skewing the immune system away from a Th2 profile. OBJECTIVE: To evaluate the efficacy and safety of intranasal AZD8848. METHODS: In a placebo-controlled single ascending dose study, AZD8848 (0.3-600 µg) was given intranasally to 48 healthy subjects and 12 patients with allergic rhinitis (NCT00688779). In a placebo-controlled repeat challenge/treatment study, AZD8848 (30 and 60 µg) was given once weekly for five weeks to 74 patients with allergic rhinitis out of season: starting 24 hours after the final dose, daily allergen challenges were given for seven days (NCT00770003). Safety, tolerability, pharmacokinetics, and biomarkers were monitored. During the allergen challenge series, nasal symptoms and lavage fluid levels of tryptase and α2-macroglobulin, reflecting mast cell activity and plasma exudation, were monitored. RESULTS: AZD8848 produced reversible blood lymphocyte reductions and dose-dependent flu-like symptoms: 30-100 µg produced consistent yet tolerable effects. Plasma interleukin-1 receptor antagonist was elevated after administration of AZD8848, reflecting interferon production secondary to TLR7 stimulation. At repeat challenge/treatment, AZD8848 reduced nasal symptoms recorded ten minutes after allergen challenge up to eight days after the final dose. Tryptase and α2-macroglobulin were also reduced by AZD8848. CONCLUSIONS: Repeated intranasal stimulation of Toll-like receptor 7 by AZD8848 was safe and produced a sustained reduction in the responsiveness to allergen in allergic rhinitis. TRIAL REGISTRATION: NCT00688779 and NCT00770003 as indicated above.
Assuntos
Alérgenos/administração & dosagem , Rinite Alérgica Perene/prevenção & controle , Receptor 7 Toll-Like/administração & dosagem , Administração Intranasal , Adulto , Método Duplo-Cego , Feminino , Humanos , Masculino , Rinite Alérgica , Receptor 7 Toll-Like/agonistas , Adulto JovemRESUMO
BACKGROUND: To assess the benefits and harms of measures designed to reduce house dust mite (HDM) exposure in the management of house dust mite-sensitive allergic rhinitis. METHODS: Systematic review of randomized controlled trials was made, in which HDM control measures have been evaluated in comparison with placebo or other HDM avoidance measures, in patients with clinically proven allergic rhinitis. RESULTS: Nine trials involving 501 participants satisfied the inclusion criteria. These trials have investigated the effectiveness of bedroom environmental control programmes involving the use of HDM impermeable bedding covers (n = 4), acaricides (n = 2), high-efficiency particulate air filters (n = 2) and, using a factorial design, acaricide and HDM impermeable bedding covers in isolation and combination (n = 1). Seven of the nine trials reported that, when compared with control, the interventions studied resulted in significant reductions in HDM load. Of the interventions studied to date, acaricides appear to be the most promising, although the findings from these studies need to be interpreted with care because of their methodological limitations. House dust mite impermeable bedding as an isolated intervention is unlikely to offer benefit. CONCLUSIONS: Trials have tended to be small and of poor methodological quality, making it difficult to offer any definitive recommendations. Interventions that achieve substantial reductions in HDM load may offer some benefit in reducing rhinitis symptoms. Isolated use of HDM impermeable bedding is unlikely to prove effective.
Assuntos
Antígenos de Dermatophagoides/imunologia , Pyroglyphidae/imunologia , Rinite Alérgica Perene/imunologia , Rinite Alérgica Perene/prevenção & controle , Animais , Humanos , Controle de Ácaros e CarrapatosRESUMO
Fatty acids (FA) are known to have a number of immunological effects and, accordingly, may play a role in the development of allergic diseases. We investigated the effect of maternal intake of FA during pregnancy on the risk of allergic rhinitis, wheeze and atopic eczema in children aged 5 years. The present study analysed data from the Finnish Type 1 Diabetes Prediction and Prevention Nutrition Study, a population-based birth cohort study with a 5-year follow-up. Complete information on maternal diet (assessed by a validated FFQ) and International Study of Asthma and Allergies in Childhood-based allergic outcomes was available for 2441 children. Cox proportional regression and logistic regression were used for the analyses. After adjusting for potential confounding variables, high maternal consumption of butter and butter spreads (hazard ratio (HR) 1.33; 95 % CI 1.03, 1.71) and higher ratio of n-6:n-3 FA (HR 1.37; 95 % CI 1.07, 1.77) during pregnancy were associated with an increased risk of allergic rhinitis in the offspring by 5 years of age. High maternal intakes of total PUFA (HR 0.71; 95 % CI 0.52, 0.96) and α-linolenic FA (HR 0.73; 95 % CI 0.54, 0.98) were associated with a decreased risk of allergic rhinitis. However, these results lost their significance after adjustment for multiple comparisons. Overall, our data suggest that maternal consumption of butter, the ratio of n-6:n-3 FA and intake of PUFA and α-linolenic FA during pregnancy may be potential determinants of allergic rhinitis in the offspring.
Assuntos
Gorduras na Dieta/administração & dosagem , Hipersensibilidade/epidemiologia , Fenômenos Fisiológicos da Nutrição Materna , Asma/epidemiologia , Asma/etiologia , Asma/fisiopatologia , Asma/prevenção & controle , Manteiga/efeitos adversos , Pré-Escolar , Estudos de Coortes , Dermatite Atópica/epidemiologia , Dermatite Atópica/etiologia , Dermatite Atópica/fisiopatologia , Dermatite Atópica/prevenção & controle , Gorduras na Dieta/efeitos adversos , Gorduras na Dieta/uso terapêutico , Ácidos Graxos Ômega-6/administração & dosagem , Ácidos Graxos Ômega-6/efeitos adversos , Feminino , Finlândia/epidemiologia , Seguimentos , Humanos , Hipersensibilidade/etiologia , Hipersensibilidade/fisiopatologia , Hipersensibilidade/prevenção & controle , Incidência , Masculino , Gravidez , Prevalência , Modelos de Riscos Proporcionais , Estudos Prospectivos , Rinite Alérgica Perene/epidemiologia , Rinite Alérgica Perene/etiologia , Rinite Alérgica Perene/fisiopatologia , Rinite Alérgica Perene/prevenção & controle , Rinite Alérgica Sazonal/epidemiologia , Rinite Alérgica Sazonal/etiologia , Rinite Alérgica Sazonal/fisiopatologia , Rinite Alérgica Sazonal/prevenção & controle , Ácido alfa-Linolênico/administração & dosagem , Ácido alfa-Linolênico/uso terapêuticoRESUMO
It has been demonstrated that Leukotriene modifiers reduce rhinitis symptoms, but montelukast preventive effect on inflammatory cells pattern in intranasal challenge studies has not been already assessed. This pilot study has been designed to explore the montelukast effects in preventing early/late inflammatory cells response to specific allergen challenge in persistent rhinitis. After a 4 week wash-out period, patients were randomised to receive montelukast/placebo for 4 weeks. Pre-post treatment nasal washing and scraping before and after specific nasal challenge were performed. No difference in baseline inflammatory cells count before and after treatment was shown between groups. Despite at a basal level a decrease of inflammatory cells in active group after treatment was observed, the statistical significance was not reached. The generalised mixed model showed that, after therapeutic interventions, the inflammatory cells increased 30' and 6 hour after challenge but, only in the active group the cells amounting was less for eosinophils (-34%), macrophages (-56%), lymphocytes (-45%) and neutrophils (-46%; p = 0.001). The longitudinal generalised linear model with just one time variable showed a decrease of all inflammatory cellular types although a significant relevance was reached only for macrophages (p = 0.038) and neutrophils (p = 0.001). The modulatory effect on neutrophils and macrophages could lead to montelukast still unexplored effects. Specific trials, sized according to the results of this pilot exploratory study, could add relevant evidences concerning the leukotrienes receptors antagonist treatment of specific rhinitis and asthma phenotypes.